HOUSTON, March 30, 2017 /PRNewswire/ -- DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, today announced that results from four studies based on the DNAtrix armed virus platform, co-authored by Juan Fueyo, MD, a professor at MD Anderson Cancer Center Department of Neuro-Oncology, will be presented at the upcoming 2017 Annual Meeting of the American Association for Cancer Research (AACR) in Washington, DC, from April 1st - 5th.
The DNAtrix armed virus platform combines the clinically effective and safe virus backbone of DNX-2401 with potent immune modulators. The studies to be presented demonstrate that DNAtrix armed viruses trigger antitumor immunity, immune memory, and an abscopal effect, ultimately leading to survival in various animal models of disease.
"Dr. Fueyo and collaborators have demonstrated the remarkable effectiveness of the DNAtrix armed virus platform," said Frank Tufaro, PhD, CEO of DNAtrix. "DNX-2440, which expresses OX40L, will enter the clinic soon for evaluation in a variety of solid tumors."
Details of the presentations (listed chronologically) are as follows:
Therapeutic potential of Delta24-ACT, a novel immunostimulatory oncolytic adenovirus, for the treatment of pediatric solid tumors: Initial study in pHGG, DIPG and osteosarcoma
Abstract Number: 704 / 21
Presenter: Marc Garcia Moure, PhD
Date: Sunday, April 2, 2017
Forced expression of GITRL in cancer cells enhances adenovirus-mediated in situ vaccination
Abstract Number: 4565 / 10
Presenter: Yisel A. Rivera-Molina, PhD
Date: Tuesday, April 4, 2017
Oncolytic adenoviruses expressing OX40L or GITRL immune modulators show antitumor effect on immune-competent mouse breast cancer models
Abstract Number: 3668 / 11
Presenter: Francisco W. Puerta Martinez, PhD
Date: Tuesday, April 4, 2017
Cancer-killing viruses combined with tumor-targeting immune checkpoint modulation elicits an in situ vaccination effect and expansion of tumor-specific T cells responsible for efficacious systemic anti-cancer activity
Abstract Number: 3680 / 23
Presenter: Hong Jiang, PhD
Date: Tuesday, April 4, 2017
For more information about DNAtrix clinical studies, please visit the website ClinicalTrials.gov: NCT02798406 (DNX-2401 + pembrolizumab), NCT02197169 (DNX-2401 ± interferon gamma), and NCT01956734 (DNX-2401 + temozolomide).
About DNAtrix Armed Virus Platform
DNAtrix is developing oncolytic viruses featuring the backbone of DNX-2401 that express immune modulatory molecules following infection of tumor cells. The first candidates, expressing various members of the TNF receptor superfamily that enhance T cell activity, have shown remarkable efficacy in animal models of cancer, including breast, melanoma, brain and lung. The first virus of this platform, DNX-2440, which expresses OX40 ligand, will enter the clinic for evaluation in a variety of solid tumors.
About DNAtrix
DNAtrix is a privately held, clinical stage, biotechnology company developing virus-driven immunotherapies for cancer. DNAtrix's lead product, DNX-2401, is a conditionally replicative oncolytic virus being studied in clinical trials for recurrent glioblastoma, a brain cancer for which there is neither a cure nor adequate treatment. The company is backed by Morningside Ventures and Mercury Fund, and has been awarded a grant from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit the company website at http://www.DNAtrix.com.
Contact
DNAtrix
Imran Alibhai, Ph.D.
S.V.P. Business Development
ialibhai@dnatrix.com
SOURCE DNAtrix